Evidence That Increased 5-HT Release Evokes Region-Specific Effects on Blood-Oxygenation Level-Dependent Functional Magnetic Resonance Imaging Responses in the Rat Brain

Neuroscience

Volumn 159, Issue 2, 2009, Pages 751-759

  Preece, M A ^a   Taylor, M J ^a   Raley, J ^a   Blamire, A ^b   Sharp, T ^a   Sibson, N R ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

5 HT; BOLD; fenfluramine; fMRI

Indexed keywords

CONTRAST MEDIUM; EXCITATORY AMINO ACID TRANSPORTER 3; FENCLONINE; FENFLURAMINE; GLUTAMATE DECARBOXYLASE; HALOTHANE; PROTEIN C FOS; PROTEIN FOS; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD OXYGENATION; BRAIN REGION; CONTROLLED STUDY; EVOKED RESPONSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERNEURON; MALE; MOTOR CORTEX; NONHUMAN; NUCLEUS ACCUMBENS; OXYGEN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; RAT;

ANIMALS; BRAIN; BRAIN MAPPING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXCITATORY AMINO ACID TRANSPORTER 3; FENCLONINE; FENFLURAMINE; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; ONCOGENE PROTEINS V-FOS; OXYGEN; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 60849088234     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.12.032     Document Type: Article

References (42)

1. Austin V.C., Blamire A.M., Allers K.A., Sharp T., Styles P., Matthews P.M., and Sibson N.R. Confounding effects of anesthesia on functional activation in rodent brain: a study of halothane and α-chloralose anesthesia. Neuroimage 24 (2005) 92-100
2. Aznavour N., Rbah L., Riad M., Reilhac A., Costes N., Descarries L., and Zimmer L. A PET imaging study of 5-HT1A receptors in cat brain after acute and chronic fluoxetine treatment. Neuroimage 33 (2006) 834-842
3. Balcioglu A., and Wurtman R.J. Dexfenfluramine enhances striatal dopamine release in conscious rats via a serotoninergic mechanism. J Pharmacol Exp Ther 284 (1998) 991-997
4. Blamire A.M., Rothman D.L., and Nixon T. Dynamic shimming update: a new approach towards optimized whole brain shimming. Magn Reson Med 36 (1996) 159-165
5. Castro E., Tordera R.M., Hughes Z.A., Pei Q., and Sharp T. Use of arc expression as a molecular marker of increased postsynaptic 5-HT function after SSRI/5-HT1A receptor antagonist co-administration. J Neurochem 85 (2003) 1480-1487
6. Chen Y.C., Galpern W.R., Brownell A.L., Matthews R.T., Bogdanov M., Isacson O., Keltner J.R., Beal M.F., Rosen B.R., and Jenkins B.G. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med 38 (1997) 389-398
7. Cohen Z., Bonvento G., Lacombe P., and Hamel E. Serotonin in the regulation of brain microcirculation. Prog Neurobiol 50 (1996) 335-362
8. Cohen Z., Bouchelet I., Olivier A., Villemure J.G., Ball R., Stanimirovic D.B., and Hamel E. Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization. J Cereb Blood Flow Metab 19 (1999) 908-917
9. Conti F., DeBiasi S., Minelli A., Rothstein J.D., and Melone M. EAAC1, a high-affinity glutamate transporter, is localized to astrocytes and GABAergic neurons besides pyramidal cells in the rat cerebral cortex. Cereb Cortex 8 (1998) 108-116
10. Curzon G., Gibson E.L., and Oluyomi A.O. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci 18 (1997) 21-25
11. de Graaf R.A., Brown P.B., McIntyre S., Rothman D.L., and Nixon T.W. Dynamic shimming update (DSU) for multislice signal acquisition. Magn Reson Med 49 (2004) 409-416
12. Devor A., Tian P., Nishimura N., Teng I.C., Hillman E.M., Narayanan S.N., Ulbert I., Boas D.A., Kleinfeld D., and Dale A.M. Suppressed neuronal activity and concurrent arteriolar vasoconstriction may explain negative blood oxygenation level-dependent signal. J Neurosci 27 (2007) 4452-4459
13. Dieguez G., Gomez B., and Lluch S. Analysis of the cerebrovascular effects of 5-hydroxytryptamine in unanesthetized goats. J Pharmacol Exp Ther 216 (1981) 599-603
14. Grasby P.M., Friston K.J., Bench C., Cowan P., Frith C.D., Liddle P.F., Frackowiak R.S.J., and Dolan R.J. Effect of the 5-HT1A partial agonist buspirone on regional cerebral blood flow in man. Psychopharmacology 108 (1992) 380-386
15. Harel N., Lee S.P., Nagaoka T., Kim D.S., and Kim S.G. Origin of negative blood oxygenation level-dependent fMRI signals. J Cereb Blood Flow Metab 22 (2002) 908-917
16. 11C]MDL100907: small animal PET and gene expression studies. Synapse 50 (2003) 251-260
17. 11C]. Way:100635-105-HT1A receptors in rat brain, assessed using in vivo microdialysis and PET after fenfluramine. Synapse 41 (2001) 150-159
18. Javed A., Van de Kar L.D., and Gray T.S. The 5-HT1A and 5-HT2A/2C receptor antagonists WAY-100635 and Ritanserin do not attenuate D-fenfluramine-induced fos expression in the brain. Brain Res 791 (1998) 67-74
19. Laruelle M., and Huang Y. Vulnerability of positron emission tomography radiotracers to endogenous competition. New insights. Q J Nucl Med 45 (2001) 124-138
20. 11C] raclopride in striatum in vivo: a rat PET study. Synapse 51 (2004) 151-157
21. Leslie R.A., and James M.F. Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends. J Pharmacol Sci 21 (2000) 314-318
22. Loubinoux I., Pariente J., Rascol O., Celsis P., and Chollet F. Selective serotonin reuptake inhibitor paroxetine modulates motor behavior through practice. A double-blind, placebo-controlled, multidose study in healthy subjects. Neuropsychologia 40 (2002) 1815-1821
23. Lucas J.J., Yamamoto A., Scearce-Levie K., Saudou F., and Hen R. Absence of fenfluramine-induced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin 1 B receptor knock-out mice. J Neurosci 18 (1998) 5537-5544
24. Martin C., and Sibson N.R. Pharmacological MRI in animal models: a useful tool for 5-HT research?. Neuropharmacology 55 (2008) 1038-1047
25. Matthews P.M., Honey G.D., and Bullmore E.T. Applications of fMRI in translational medicine and clinical practice. Nat Rev Neurosci 7 (2006) 732-744
26. McKie S., Del-Ben C., Elliott R., Williams S., del Vai N., Anderson I., and Deakin J.F.W. Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology 180 (2005) 680-686
27. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1986), Academic Press, New York
28. Pinborg L.H., Adams K.H., Yndgaard S., Hasselbalch S.G., Holm S., Kristiansen H., Paulson O.B., and Knudsen G.M. [18F]Altanserin binding to human 5HT2A receptors is unaltered after citalopram and pindolol challenge. J Cereb Blood Flow Metab 24 (2004) 1037-1045
29. Preece M., Mukherjee B., Huang C.L.-H., Hall L.D., Leslie R.A., and James M.F. Detection of pharmacologically mediated changes in cerebral activity by functional magnetic resonance imaging: the effects of sulpiride in the brain of the anaesthetised rat. Brain Res 916 (2001) 107-114
30. Preece M.A., Sibson N.R., Raley J.M., Blamire A., and Styles P. Region specific effects of a tyrosine-free amino acid mixture on amphetamine-induced changes in BOLD fMRI signal in the rat brain. Synapse 61 (2007) 925-932
31. 1A receptors in normal male volunteers: normative data and relationship to methodological, demographic, physiological, and behavioral variables. Neuroimage 15 (2002) 620-632
32. Scanley B.E., Kennan R.P., and Gore J.C. Changes in rat cerebral blood volume due to modulation of the 5-HT1A receptor measured with susceptibility enhanced contrast. Brain: MRIResources 913 (2001) 149-155
33. Seeman P., and Kapur S. Anesthetics inhibit high-affinity states of dopamine D2 and other G-linked receptors. Synapse 50 (2003) 35-40
34. Series H.G., Cowen P.J., and Sharp T. p-Chloroamphetamine (PCA), 3,4-methylenedioxy-methamphetamine (MDMA) and d-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5-HT in vivo. Psychopharmacology 116 (1994) 508-514
35. Shmuel A., Augath M., Oeltermann A., and Logothetis N.K. Negative functional MRI response correlates with decreases in neuronal activity in monkey visual area V1. Nat Neurosci 9 (2006) 569-577
36. Slifstein M., Narendran R., Hwang D.R., Sudo Y., Talbot P.S., Huang Y., and Laruelle M. Effect of amphetamine on [(18)F]fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: single bolus and bolus plus contrast constant infusion studies. Synapse 54 (2004) 46-63
37. Smith A.T., Williams A.L., and Singh K.D. Negative BOLD in the visual cortex: evidence against blood stealing. Hum Brain Mapp 21 (2004) 213-220
38. Stark J.A., Davies K.F., Williams S.R., and Luckman S.M. Functional magnetic resonance imaging and c-fos mapping in rats following an anorectic dose of m-chlorophenylpiperazine. Neuroimage 31 (2006) 1228-1237
39. Toda N., and Fujita Y. Responsiveness of isolated cerebral and peripheral arteries to serotonin, norepinephrine, and transmural electrical stimulation. Circ Res 33 (1973) 98-104
40. Udo de Haes J.I., Harada N., Elsinga P.H., Maguire R.P., and Tsukada H. Effect of fenfluramine-induced increases in serotonin release on [18F]MPPF binding: a continuous infusion PET study in conscious monkeys. Synapse 59 (2006) 18-26
41. Villalón C.M., and Centurión D. Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol 376 (2007) 45-63
42. Völlm B.A., de Araujo I.E., Cowen P.J., Rolls E.T., Kringelbach M.L., Smith K.A., Jezzard P., Heal R.J., and Matthews P.M. Methamphetamine activates reward circuitry in drug naïve human subjects. Neuropsychopharmacology 29 (2004) 1715-1722